About The 2024 Event
The 8th Complement-Based Drug Development Summit reunited 100+ preclinical, translational, and clinical experts at the forefront of complement-based drug development.Â
With new excitement and energy in the complement field, following Novartis’ approval, attendees joined us to dig deep into strategic targeting within the complement cascade, mitigating toxicity, the potential for complement combinations and moving into inflammatory and autoimmune diseases beyond rare disease.
Who Was On The Guest List?
A highly focused audience comprised of executives working in discovery, preclinical, translational, clinical, PK/PD toxicology and medical affairs enabled attendees to gain unparalleled information sharing and brainstorming for those across the entire complement landscape including large pharma, biotech, and service providers.Â
